AC
IART icon

Ascend Capital’s Integra LifeSciences IART Stock Holding History

Ascend Capital’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-22,667
Closed -$443K – 210
2013
Q4 		$443K Buy
+22,667
New +$416K 0.01% 177

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Ascend Capital's IART Position: Q1 2014 in Review

Ascend Capital sold out of Integra LifeSciences (IART) in Q1 2014, closing a stake of 22,667 shares — an estimated $443K sold.

Ascend Capital first reported a position in IART in Q4 2013 and held it in 1 quarter. The position peaked at $443K in Q4 2013. 144 funds tracked by Wall St. Rank hold IART as of Q1 2014.

  • Ascend Capital reported no remaining Integra LifeSciences position as of Q1 2014 after selling out during the quarter.
  • Ascend Capital sold 22,667 Integra LifeSciences shares in Q1 2014, an estimated $443K.
  • Ascend Capital first reported a position in Integra LifeSciences in Q4 2013 and held it in 1 quarter.
  • Ascend Capital's Integra LifeSciences position peaked at $443K in Q4 2013.
  • 144 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2014.

Based on Ascend Capital's 13F filing for Q1 2014, filed 14 May 2014.